New Late-Breaking Analyses from Landmark COAPT(TM) Trial Show Benefits of Abbott`s MitraClip(TM) Device
(WorldNews Health)

NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive late-breaking data from two separate analyses of the COAPTTM Trial showing additional key benefits from treatment with MitraClipTM for heart failure patients with clinically significant secondary (or functional) mitral regurgitation (MR), or leaky heart valve. Both data sets were presented today at the American College of Cardiology`s (ACC) 68th Annual Scientific Session. On Thursday, the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for MitraClip to treat secondary mitral regurgitation based on the COAPT Trial data. During the late-breaking session today at ACC, MitraClip...